Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is ... Neutral | $759.00|$940.00 | |David Risinger |Leerink Partners |Raises |Outperform | $834.00|$762. ...

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

At the low end of effective tax rates is Regeneron Pharmaceuticals (NASDAQ: REGN), which has issued effective tax rate guidance for 2025 of 9% to 11%. With manufacturing split between Rensselaer ...

TD Cowen also adjusted its price target for Regeneron to $1,030, lowering revenue estimates for the Eylea franchise due to increased market competition. Leerink Partners reduced its price target ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

On the bright side, Leerink Partners upgraded Regeneron to a “strong-buy,” proving at least one analyst still believes in scientific miracles and stock rebounds. Despite the lukewarm analyst sentiment ...